| 李永昊,柳江燕,崔正存.99Tcm-3PRGD2和99Tcm-MIBI用于诊断与治疗分化型甲状腺癌研究进展[J].中国医学影像技术,2025,41(10):1768~1771 |
| 99Tcm-3PRGD2和99Tcm-MIBI用于诊断与治疗分化型甲状腺癌研究进展 |
| Research progresses of 99Tcm-3PRGD2 and 99Tcm-MIBI for diagnosis and treatment of differentiated thyroid cancer |
| 投稿时间：2025-02-25 修订日期：2025-10-14 |
| DOI：10.13929/j.issn.1003-3289.2025.10.035 |
| 中文关键词: 甲状腺肿瘤 放射性核素显像 有机锝化合物 |
| 英文关键词:thyroid neoplasms radionuclide imaging organotechnetium compounds |
| 基金项目: |
|
| 摘要点击次数: 96 |
| 全文下载次数: 40 |
| 中文摘要: |
| 分化型甲状腺癌(DTC)占所有甲状腺癌的95%以上。99Tcm-3PRGD2能特异性结合恶性肿瘤新生血管内皮细胞和肿瘤细胞表面高度表达的整合素αvβ3受体,特异性和安全性较高,可用于诊断DTC及其转移灶、评估抗血管生成及抗αvβ3药物疗效。99Tcm-MIBI为非特异性亲肿瘤显像剂,与99Tcm-3PRGD2联合应用或可提高诊断效能。本文就99Tcm-3PRGD2和99Tcm-MIBI用于诊断与治疗DTC研究进展进行综述。 |
| 英文摘要: |
| Differentiated thyroid cancer (DTC) accounts for more than 95% of all thyroid cancers. 99Tcm-3PRGD2 can specifically bind to integrin αvβ3 receptors highly expressed on the surfaces of neovascular endothelial cells and tumor cells in malignant tumors. With high specificity and safety, 99Tcm-3PRGD2 can not only be used for diagnosing DTC and its metastases, but also evaluating the efficacy of anti-angiogenic and anti-αvβ3 therapies. 99Tcm-MIBI is a non-specific tumor-avid imaging agent, which may improve diagnostic accuracy combined with 99Tcm-3PRGD2. The research progresses of 99Tcm-3PRGD2 and 99Tcm-MIBI for diagnosis and treatment of DTC were reviewed in this article. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
